CyFlow™ CD19 Biotin
| Alternative Name: | B4 |
| Antibody: | Yes |
| Antigen: | CD19 |
| Application: | Flow cytometry |
| Clonality: | monoclonal |
| Clone: | 4G7 |
| Field of Interest: | Immunophenotyping |
| Format/Fluorochrome: | Biotin |
| Isotype: | IgG1 |
| Regulatory Status: | RUO |
| Source Species: | Mouse |
| Target Species: | Human |
| Product number: | CG759445 |
For Research Use Only
| Concentration Unit | mg/mL |
| Concentration | 1 |
| Quantity | 0.1 mg |
| Volume | 0.1 mL |
| Immunogen | Human Chronic Lymphocytic Leukemia (CLL) cells |
| Background Information | CD19 is a transmembrane glycoprotein of Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), this complex signals to decrease B cell treshold for activation by the antigen. Besides being signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity. |
| Usage | The reagent is designed for indirect immunofluorescence analysis by Flow Cytometry. Working concentrations should be determined by the investigator. |
| Storage Buffer | The reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Reinherz EL, Haynes BF, Nadler LM, Bernstein ID: Leukocyte Typing II, Volume 1 Human T Lymphocytes. Springer Verlag, New York. 1986; 1:1‑549. < PMID: Springer 8587-5 > | Muench MO, Roncarolo MG, Namikawa R: Phenotypic and functional evidence for the expression of CD4 by hematopoietic stem cells isolated from human fetal liver. Blood. 1997 Feb 15; 89(4):1364‑75. < PMID: 9028960 > | Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T: Triggering Fc alpha‑receptor I (CD8{09} recruits neutrophils as effector cells for CD20‑directed antibody therapy. J Immunol. 2000 Nov 15; 165(10):5954‑61. < PMID: 11067958 > | Dubois B, Massacrier C, Caux C: Selective attraction of naive and memory B cells by dendritic cells. J Leukoc Biol. 2001 Oct; 70(4):633‑41. < PMID: 11590201 > | Basu S, Lynne CM, Ruiz P, Aballa TC, Ferrell SM, Brackett NL: Cytofluorographic identification of activated T‑cell subpopulations in the semen of men with spinal cord injuries. J Androl. 2002 Jul-Aug; 23(4):551‑6. < PMID: 12065463 > | Porcellini S, Vallanti G, Nozza S, Poli G, Lazzarin A, Tambussi G, Siccardi AG, Grassi F: Improved thymopoietic potential in aviremic HIV infected individuals treated with HAART by intermittent IL‑2 administration. AIDS. 2003 Jul 25; 17(11):1621‑30. < PMID: 12853744 > | Treusch M, Vonthein R, Baur M, Günaydin I, Koch S, Stübiger N, Eckstein AK, Peter HH, Ness T, Zierhut M, Kötter I: Influence of human recombinant interferon‑alpha2a (rhIFN‑alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease. Rheumatology (Oxford). 2004 Oct; 43(10):1275‑82. < PMID: 15252211 > | Köller M, Zwölfer B, Steiner G, Smolen JS, Scheinecker C: Phenotypic and functional deficiencies of monocyte‑derived dendritic cells in systemic lupus erythematosus (SLE) patients. Int Immunol. 2004 Nov; 16(11):1595‑604. < PMID: 15381672 > | Martino V, Tonelli R, Montemurro L, Franzoni M, Marino F, Fazzina R, Pession A: Down‑regulation of MLL‑AF9, MLL and MYC expression is not obligatory for monocyte‑macrophage maturation in AML‑M5 cell lines carrying t(9: 11)(p22: q23). Oncol Rep. 2006 Jan; 15(1):207‑11. < PMID: 16328057 > | Andersen P, Pedersen MW, Woetmann A, Villingshøj M, Stockhausen MT, Odum N, Poulsen HS: EGFR induces expression of IRF‑1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. Int J Cancer. 2008 Jan 15; 122(2):342‑9. < PMID: 17918184 >